The company's financial position has deteriorated into a negative equity state of -$844.6K, exacerbated by a surge in total debt to $3.0M as of 2024Q4.
| Total Current Assets | 3.17M | 7.38M | 3.17M | 2.46M | 2.4M | 820.39K |
| Cash & Short-Term Investments | 457.74K | 758.62K | 457.74K | 54.1K | 27.56K | 28.76K |
| Cash Only | 457.74K | 758.62K | 457.74K | 54.1K | 27.56K | 28.76K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.36M | 1.07M | 2.36M | 519.55K | 2.32M | 750.35K |
| Days Sales Outstanding | 137.42 | 82.56 | 158.72 | 36.92 | 142.72 | 66.51 |
| Inventory | 80.81K | 335.36K | 80.81K | 126.26K | 46.91K | 41.27K |
| Days Inventory Outstanding | 11.27 | 32.46 | 8.18 | 13.34 | 3.89 | 4.87 |
| Other Current Assets | 1.07M | 116.25K | 73.92K | 373.68K | 0 | 0 |
| Total Non-Current Assets | 609K | 25.34M | 609K | 2.03M | 506.34K | 592.38K |
| Property, Plant & Equipment | 371.67K | 2.29M | 371.67K | 446K | 506.34K | 592.38K |
| Fixed Asset Turnover | 8.44x | 2.06x | 14.62x | 11.52x | 11.74x | 6.95x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 23.05M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 70.9M | 0 | 204K | 0 | 0 | 0 |
| Other Non-Current Assets | 33.33K | 0 | 33.33K | 1.58M | 0 | 0 |
| Total Assets | 3.78M | 32.72M | 3.58M | 4.49M | 2.9M | 1.41M |
| Asset Turnover | 0.09x | 0.14x | 1.52x | 1.14x | 2.05x | 2.91x |
| Asset Growth % | -109.38% | 814.62% | -20.26% | 54.46% | 105.62% | - |
| Total Current Liabilities | 2.72M | 2.37M | 2.72M | 1.12M | 2.56M | 2.07M |
| Accounts Payable | 1.3M | 779.28K | 1.3M | 172.63K | 104.65K | 46.93K |
| Days Payables Outstanding | 69.92 | 75.44 | 131.48 | 18.24 | 8.67 | 5.54 |
| Short-Term Debt | 690.97K | 256.06K | 582.45K | 0 | 0 | 512.82K |
| Deferred Revenue (Current) | 1.43M | 111.98K | 63.49K | 7.94K | 1.36M | 812.16K |
| Other Current Liabilities | 554.38K | 262.62K | 554.38K | 0 | 0 | 0 |
| Current Ratio | 1.17x | 3.12x | 1.17x | 2.19x | 0.94x | 0.40x |
| Quick Ratio | 1.14x | 2.98x | 1.14x | 2.08x | 0.92x | 0.38x |
| Cash Conversion Cycle | 78.77 | 39.59 | 35.42 | 32.02 | 137.93 | 65.84 |
| Total Non-Current Liabilities | 2.34M | 4.37M | 2.34M | 118.98K | 248.63K | 261.82K |
| Long-Term Debt | 2.33M | 4.1M | 2.33M | 0 | 0 | 0 |
| Capital Lease Obligations | 377.84K | 272.36K | 10.23K | 118.98K | 248.63K | 261.82K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 5.06M | 6.74M | 5.06M | 1.24M | 2.8M | 2.33M |
| Total Debt | 3.03M | 4.86M | 3.03M | 332.55K | 452.04K | 925.97K |
| Net Debt | 2.57M | 4.11M | 2.57M | 278.45K | 424.49K | 897.2K |
| Debt / Equity | -2.37x | 0.19x | - | 0.10x | 4.49x | - |
| Debt / EBITDA | -2.15x | - | - | 1.22x | - | 1.71x |
| Net Debt / EBITDA | -1.83x | - | - | 1.02x | - | 1.66x |
| Interest Coverage | 1.71x | 16.78x | -0.23x | 3.35x | 5.42x | 2.77x |
| Total Equity | -1.28M | 25.99M | -1.48M | 3.25M | 100.68K | -914.91K |
| Equity Growth % | -234.59% | 1853.78% | -145.65% | 3123.54% | 111% | - |
| Book Value per Share | -2.17 | 44.18 | -2.52 | 12.38 | 0.38 | -3.49 |
| Total Shareholders' Equity | -844.61K | 26.63M | -1.05M | 3.74M | 563.11K | -775.94K |
| Common Stock | 0 | 0 | 0 | 0 | 6.02K | 5.6K |
| Retained Earnings | -985.99K | 8.89M | -985.99K | -461.35K | -591.54K | -1.05M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 18.88K | -143.07K | 18.88K | -7.29K | 9.57K | 10.85K |
| Minority Interest | -433.14K | -644.83K | -433.14K | -490.05K | -462.43K | -138.97K |
Imminent liquidity insolvency risk
According to the most recent quarterly filings, NewGenIvf's total assets have plummeted from $70.8M in 2022Q4 to just $3.8M by 2024Q4, signaling a severe and rapid contraction in the company's underlying resource base and overall business viability within the competitive reproductive healthcare sector.
The dramatic reduction in asset scale suggests that the company is struggling to maintain its operational footprint, likely due to persistent cash burn and the inability to generate sufficient returns on invested capital. Investors should monitor whether this trajectory indicates a fundamental downsizing of the business model or an impending inability to sustain operations.
As reported in financial statements, the company's debt load has surged to $3.0M in 2024Q4, a significant increase from the $452.0K reported in 2022Q4, which places immense pressure on a balance sheet that now reflects a negative equity position of -$844.6K.
The shift toward higher debt levels in the face of shrinking assets and negative equity suggests that the company is relying on external financing to cover operational shortfalls rather than internal cash generation. This reliance on debt, combined with a lack of equity cushion, significantly elevates the risk of default if clinical revenue does not stabilize immediately.
Based on the latest reported figures, NewGenIvf has transitioned to a negative equity position of -$844.6K, a stark reversal from the $68.3M in equity recorded in 2022Q4, which highlights the severe impact of accumulated losses on the company's capital structure.
The erosion of shareholder equity to a negative value indicates that historical losses have completely exhausted the company's net worth. This development suggests that the firm is effectively operating on borrowed capital, which warrants extreme caution regarding the long-term sustainability of its current business model.
Data from recent filings indicates that cash reserves have dwindled to $457.7K as of 2024Q4, providing a dangerously thin buffer against the company's ongoing operating losses and the $5.1M in total liabilities currently weighing on the balance sheet.
While the current ratio of 1.17 might appear superficially adequate, the absolute level of cash is insufficient to support the company's high-cost clinical infrastructure for an extended period. The mismatch between liquid assets and total liabilities suggests that the company may face an imminent liquidity crisis without immediate capital injection.
Financial disclosures reveal that the company's asset base has been stripped of significant value, with net PPE falling to $371.7K in 2024Q4, suggesting that the firm lacks the tangible collateral necessary to secure favorable financing terms during this period of distress.
The absence of goodwill and the minimal investment in PPE imply that the company's value is not anchored in durable physical or intangible assets, making it highly vulnerable to operational disruptions. This lack of tangible backing makes the company's reliance on debt even more concerning for potential investors.
Quick answers to the most common questions about buying NIVFW stock.
As of 2025, NewGenIvf Group Limited (NIVFW) had total assets of $32.7M including $7.4M in current assets.
NewGenIvf Group Limited (NIVFW) carries total debt of $4.9M, offset by $0.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
NewGenIvf Group Limited (NIVFW) has total shareholders' equity (book value) of $26.6M ($44.18 book value per share). Book value represents the net worth of the company belonging to common stock holders.
NewGenIvf Group Limited (NIVFW) reported a current ratio of 3.12x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.